One possibility for the lack of efficacy of Lebrikizumab in mild asthma patients might be that IL-13 may not be the cytokine responsible for the symptoms in such a patient population, and a role for IL-13 may be significant only in more severe forms of the disease [103]. This evidence concerns the gene IL13 and asthma.